INPPL1 — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL489020	0.88	12/20
SCHEMBL582185	0.59	12/20
SCHEMBL258268	0.54	12/20
SCHEMBL1771611	0.52	12/20
SCHEMBL2472745	0.57	11/20
SCHEMBL109597	0.52	11/20
SCHEMBL2175835	0.52	11/20
SCHEMBL1593348	0.50	11/20
SCHEMBL130697	0.71	10/20
SCHEMBL329313	0.68	10/20
SCHEMBL522291	0.59	10/20
SCHEMBL842250	0.59	10/20
SCHEMBL569537	0.57	9/20
SCHEMBL1641458	0.54	9/20
Menadiol Diphosphoric Acid (SCHEMBL515181)	0.50	9/20
SCHEMBL2330382	0.46	9/20
SCHEMBL554382	0.44	9/20
SCHEMBL488916	0.72	8/20
SCHEMBL842728	0.63	8/20
SCHEMBL1756537	0.59	8/20

Clinical trials — most relevant to INPPL1 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
The Effect of the Preoperative Oral Carbohydrate Attenuating Immediate Postoperative Insulin Resistance on PI3K Dependent Signaling Pathway	PHASE4	COMPLETED
Efficacy of Lithium Against Chemotherapy Induced Neutropenia in Breast Cancer Patients	PHASE3	COMPLETED
Study Evaluating Toxicity & Efficacy of Lenalidomide(Revlimid®)in Chemotherapy-Naïve AIPC Patients	PHASE2	COMPLETED
Rapamycin Treatment for Activated Phosphoinositide 3-Kinase δ Syndrome	PHASE1/PHASE2	COMPLETED
Evexomostat Plus PI3K or AKT Inhibitor and Fulvestrant in Patients With a PI3K Alteration and HR+/Her2- Breast Cancer	PHASE1/PHASE2	RECRUITING
Everolimus for Children With Recurrent or Progressive Ependymoma	PHASE2	COMPLETED
RAD001 in Pheochromocytoma or Nonfunctioning Carcinoid	PHASE2	COMPLETED
Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma	PHASE1	COMPLETED
Analysis of Tissues From Patients in Trial of Myo-Inositol to Prevent Lung Cancer	PHASE1	COMPLETED
PET Imaging of Brain mGluR5 Receptors Using [18F]SP203	PHASE1	COMPLETED
Bioequivalence Study of Tacrolimus in Healthy Volunteers	PHASE1	COMPLETED
Palliative Thoracic Radiotherapy Plus BKM120	PHASE1	COMPLETED
Evaluating MED2005 & Nitrostat Bioavailability	PHASE1	COMPLETED
Nilotinib in Huntington's Disease	PHASE1	UNKNOWN
Study of the Pathophysiological Mechanisms Involved in Bleeding Events	nan	COMPLETED
NGS in Gallbladder Cancer and Response to Treatment	nan	RECRUITING
Partial PTEN Deletion in Breast Cancer	nan	UNKNOWN
The Study Aims to Investigate the Effects of Oral Inositols on Insulin-resistance in Children With Obesity.	nan	UNKNOWN
Evaluation of Plasma Sphingosine-1-Phosphate as A Diagnostic and Prognostic Biomarkers of Community-Acquired Pneumonia	nan	UNKNOWN
Duality of Lipids: the Athlete's Paradox	nan	COMPLETED
p-AKT Expression on Clinical Outcomes in Malignant Lymphoma	nan	COMPLETED
Molecular Markers of Human Sperm Function	nan	WITHDRAWN
Combining Gene Variants to Improve Risk Prediction for Metabolic (Dysfunction)- Associated Fatty Liver Disease and Its Progression to Cirrhosis in Indian Individuals With Type 2 Diabetes	nan	COMPLETED
Vulvodynia: Identification of Potential Relevant Biomarkers	nan	COMPLETED
Glycine and Magnesium+Thiamine for the Treatment of Primary Ciliary Dyskinesia	nan	RECRUITING
Plaque Calcium Characterization and Ruptured Plaques	nan	UNKNOWN
Exome Sequencing for Atypical Femoral Fractures	nan	COMPLETED
Composition & Function of Sarcoplasmic Reticulum in Persons With the Metabolic Syndrome	nan	COMPLETED
Biomarkers in Samples From Young Patients With Acute Myeloid Leukemia	nan	COMPLETED
Cardiovascular Effects of Empagliflozine	nan	UNKNOWN

Related proteins — ESM-2 sequence neighbours (a INPPL1 binder may also engage these)

Protein	Name	Similarity
A0A8I3NFE2	—	1.000	A0A8I3NFE2 →
Q9WVR3	—	1.000	Q9WVR3 →
D7PF45	—	1.000	D7PF45 →
Q6P549	—	1.000	Q6P549 →
Q2I6J1	—	0.995	Q2I6J1 →
INPP5D	Phosphatidylinositol 3,4,5-trisphosphate 5-phosphatase 1	0.993	landscape →
P97573	—	0.992	P97573 →
Q9ES52	—	0.989	Q9ES52 →
Q6P4S2	—	0.988	Q6P4S2 →
Q2I6J0	—	0.986	Q2I6J0 →
Q5M824	—	0.985	Q5M824 →
Q61120	—	0.984	Q61120 →
Q5R7W7	—	0.983	Q5R7W7 →
P98083	—	0.983	P98083 →
PTPN14	Tyrosine-protein phosphatase non-receptor type 14	0.982	landscape →
E9PUQ8	—	0.981	E9PUQ8 →
Q9ULM0	—	0.981	Q9ULM0 →
PIK3C2B	Phosphatidylinositol 4-phosphate 3-kinase C2 domain-containing subunit beta	0.980	landscape →
KAT2B	Histone acetyltransferase KAT2B	0.980	landscape →
O54967	—	0.980	O54967 →
SHC1	SHC-transforming protein 1	0.980	landscape →
Q5F479	—	0.980	Q5F479 →
PTPN21	Protein-tyrosine phosphatase D1	0.980	landscape →
Q812E4	—	0.980	Q812E4 →
Q62925	—	0.980	Q62925 →
B5DFA1	—	0.980	B5DFA1 →
Q62136	—	0.979	Q62136 →
Q9WVR1	—	0.979	Q9WVR1 →
Q9BYX2	—	0.979	Q9BYX2 →
Q5RJI5	—	0.979	Q5RJI5 →